Bio Pharma Dive

AUGUST 9, 2023

Third Rock-founded Decibel, which has shed much of its value since a 2021 IPO, expected to run out of money within a year.

Genetics 245

Genetics Medicine 245

Bio Pharma Dive

JUNE 29, 2022

The two drugmakers joined a long list of investors, including Pfizer and Sanofi, that have been funding the startup’s plan to develop a new type of lipid nanoparticle technology.

Genetics 255

Genetics Medicine Development 255

Pharmaceutical Technology

JANUARY 16, 2023

CARsgen Therapeutics has announced a col labor ation with Huadong Medicine to commercialise zevorcabtagene autoleucel (zevor-cel), CT053, in mainland China. It comprises autologous T cells that are modified genetically with a CAR including a complete human anti-BCMA single-chain fragment variant that has a high binding affinity.

Medicine 298

Medicine Gene Therapy Production Gene 298

Pharmaceutical Technology

FEBRUARY 13, 2024

The MHRA kicks off phase two of the Yellow Card biobank to explore the genetic link to side effects of direct oral anticoagulants.

Biobanking 277

Biobanking Medicine Genetics 277

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 30, 2024

Researchers see a greater need for new generation therapeutics to propel precision medicine. The development of innovative therapeutic approaches in healthcare encompass a variety of fields, including gene therapy, personalized medicine, immunotherapy, and advanced biologics.

Medicine 189

Medicine Research Gene Therapy Genetics 189

AuroBlog - Aurous Healthcare Clinical Trials blog

FEBRUARY 18, 2024

Indian healthcare industry is of the view that emergence of genetic diagnostics will be a paradigm shift towards personalized medicine. Through the ever-evolving landscape of healthcare, the role of genetic diagnostics offers personalized insights and proactive solutions for disease management and prevention.

Genetics 189

Genetics Medicine Development Drugs 189

Pharmaceutical Technology

MARCH 24, 2023

Moderna has entered a strategic partnership with Generation Bio for the development of non-viral genetic medicines. Moderna’s biological and technical expertise will be combined with core technologies of the non-viral genetic medicine platform from Generation Bio.

Genetics 130

Genetics Medicine Development In-Vivo 130

Bio Pharma Dive

APRIL 6, 2022

Facing mounting competition to its top-selling drug Eylea, Regeneron is teaming up with ViGeneron to develop a genetic medicine for an inherited retinal disease.

Gene Therapy 344

Gene Therapy Gene Genetics Medicine 344

XTalks

DECEMBER 18, 2024

CAH is a group of rare genetic disorders affecting the adrenal glands, which produce essential hormones like cortisol, aldosterone and androgens. Trial data for both the pediatric and adult trials were published in The New England Journal of Medicine. Crenessity marks the third approved drug for Neurocrine.

Genetics 116

Genetics Hormones Trials Drugs 116

Bio Pharma Dive

APRIL 25, 2024

“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.

Gene Editing 301

Gene Editing Gene Genetics Medicine 301

Drug Patent Watch

DECEMBER 9, 2024

This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine. Let’s embark on a journey to uncover the secrets of nature’s medicine cabinet and the legal frameworks that protect these discoveries.

Medicine 97

Medicine Drugs Production Development 97

Bio Pharma Dive

JUNE 15, 2023

Lilly will pay the genetic medicine specialist $60 million upfront to work together on a treatment targeting a risk factor known as Lp(a).

Gene Editing 316

Gene Editing Gene Genetics Medicine 316

Pharmaceutical Technology

JULY 7, 2022

Genetic mutations, both germline and acquired, are behind a large proportion of the most debilitating and sometimes life-threatening human diseases. But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Bio Pharma Dive

MARCH 1, 2023

At a time when many startups have struggled to gain cash, the biotech has raised another $135 million to back its research, a new twist on genetic medicine.

Genetics 311

Genetics Medicine Research 311

Bio Pharma Dive

FEBRUARY 15, 2024

The partnership will use Intellia's "DNA writing” technology, and initially focus on people with the lung disease who have limited or no available treatment options.

Genetics 177

Genetics Medicine DNA 177

Bio Pharma Dive

DECEMBER 8, 2023

million, while a competing genetic medicine also cleared Friday is priced at $3.1 Casgevy, the first CRISPR therapy approved by the FDA, will cost $2.2

Gene Therapy 300

Gene Therapy Gene Genetics Medicine 300

Pharmaceutical Technology

MAY 17, 2023

Under the deal, Prevail obtains exclusive rights to use Scribe’s CRISPR X-Editing (XE) technologies to develop the medicines. The deal will see the integration of Scribe’s new CRISPR by Design approach and Prevail’s expertise in developing genetic medicines for neurological disorders for specific genetic targets.

Genetics 130

Genetics Medicine In-Vivo Gene Therapy 130

Bio Pharma Dive

SEPTEMBER 12, 2024

Spun out of research at Nationwide Children’s Hospital, Vironexis claims it will be the first company to start a study testing a cancer drug delivered via the adeno-associated viruses commonly used in genetic medicines.

Gene Therapy 278

Gene Therapy Gene Genetics Trials 278

Scienmag

APRIL 14, 2022

In a Policy Forum, Anna Lewis and colleagues argue that, for researchers and others who want to invoke genetic ancestry, there is a scientific and ethical imperative to move away from continental ancestry categories and to instead embrace a view of genetic ancestry that reflects continuous variation and historical depth.

Genetics 123

Genetics Medicine Research 123

Bio Pharma Dive

JANUARY 24, 2024

An 11-year-old boy born deaf can hear after receiving Lilly's genetic medicine. Others, including biotechs in China and Regeneron in the U.S., are taking aim at the same drug target.

Gene Therapy 293

Gene Therapy Gene Genetics Medicine 293

Bio Pharma Dive

AUGUST 24, 2022

The New York biotech will invest in and develop up to three drugs with Gensaic, an emerging startup aiming to use the viruses that infect bacteria to deliver genetic medicines.

Gene Therapy 285

Gene Therapy Bacteria Gene Drugs 285

Bio Pharma Dive

JUNE 15, 2021

A deal with biotech startup Capsida, which recently raised $140 million, gives CRISPR access to a Caltech technology that aims to improve the delivery of genetic medicines.

Gene Editing 281

Gene Editing Gene Genetics Development 281

Bio Pharma Dive

APRIL 1, 2022

Taysha Gene Therapies is narrowing its research efforts and cutting around 35% of its workforce, the latest in a series of layoffs announced by makers of genetic medicines.

Gene Therapy 278

Gene Therapy Gene Development Genetics 278

Bio Pharma Dive

FEBRUARY 12, 2021

Lysosomal storage disorders, diseases of cellular metabolism gone wrong, are the focus of a fast-expanding lineup of experimental genetic medicines, a research boom that recalls biotech's roots.

Gene Therapy 278

Gene Therapy Gene Genetics Medicine 278

Bio Pharma Dive

MARCH 23, 2023

The biotech plans to use Generation Bio’s nonviral delivery technology to get nucleic acid-based therapies to immune cells and into the liver.

Genetics 161

Genetics Medicine 161

Bio Pharma Dive

JANUARY 6, 2022

The French pharma cited a "change in strategic direction" for ending a long-running pact focused on genetic medicines for blood diseases, led by a sickle cell treatment in early testing.

Genetics 278

Genetics Medicine 278

Bio Pharma Dive

JUNE 2, 2022

He'll lead Tessera Therapeutics, a well-funded genetic medicine startup. Severino left the pharma company in April after eight years as its chief scientist and then president.

Pharma Companies 269

Pharma Companies Genetics Scientist Medicine 269

pharmaphorum

SEPTEMBER 6, 2024

Eli Lilly signs another genetic medicines deal, this time with Genetic Leap, a start-up that applies AI to the discovery of RNA-targeted drugs.

Genetics 104

Genetics RNA Medicine Drugs 104

Bio Pharma Dive

MARCH 15, 2021

Softbank and Fidelity joined a large group of investors in a $525 million Series C investment into Elevate, a high-powered genetic medicine startup with an unusual business model.

Gene Therapy 264

Gene Therapy Gene Genetics Medicine 264

Bio Pharma Dive

OCTOBER 3, 2023

The longtime partners believe that, by combining their technologies, they can create “in vivo” genetic medicines for nervous system and muscular disorders.

Gene Editing 258

Gene Editing In-Vivo Gene Genetics 258

Pharmaceutical Technology

FEBRUARY 27, 2024

Making therapies feasible from biological, regulatory, and commercial standpoints drives scalable genetic medicine.

Gene Therapy 246

Gene Therapy Gene Genetics Medicine 246

Bio Pharma Dive

OCTOBER 24, 2022

The biotech is the latest in a growing list of genetic medicine developers to sell themselves near record stock lows amid a challenging funding environment.

Gene Therapy 259

Gene Therapy Gene Genetics Medicine 259

Bio Pharma Dive

SEPTEMBER 9, 2021

billion, expands Lilly's work in genetic medicine research. An agreement with the Dutch biotech, which could be worth as much as $1.3

RNA 258

RNA Genetics Medicine Research 258

Bio Pharma Dive

NOVEMBER 12, 2024

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in people living with the nerve-destroying disorder.

RNA 161

RNA Genetics Medicine 161

Bio Pharma Dive

MARCH 28, 2022

The study setback raises questions over how well a type of genetic medicine can work in adults with central nervous system disorders like ALS.

Genetics 246

Genetics Trials Medicine Drugs 246

Bio Pharma Dive

JULY 28, 2023

The British pharma is deepening its investment in genetic medicine through a deal for a group of Pfizer’s gene therapy delivery tools, while the New York giant cuts back.

Gene Therapy 246

Gene Therapy Gene Genetics Medicine 246

Bio Pharma Dive

DECEMBER 16, 2021

The new facility cost nearly $70 million to build, and is part of a major push by the pharma giant to become a leader in genetic medicine manufacturing.

Gene Therapy 241

Gene Therapy Gene Genetics Manufacturing 241